세계의 기능유전체학 시장(2023-2033년) : 제품, 기술, 용도, 최종사용자, 지역별 분석 및 예측

“The global functional genomics market is estimated to reach $46.24 billion in 2033, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 14.04% during the forecast period 2023-2033.”

Growth in the global functional genomics market is driven by the increasing investments by the government and private organizations and the increasing realization of the need for personalised medicine and therapies.

USP of the Report

• Vast segmentation of the report
• Product specifications and comparative analysis
• Market dynamic analysis of the opportunities, trends, and challenges in the market
• Competitive benchmarking of key players for each product type
• Growth share analysis for key segments

Analyst Perspective

According to Swati Sood, Principal Analyst, BIS Research, "Global functional genomics market is a one of the major markets going to be involved in the revolution of precision medicine in the coming years. Functioanl genomics helps us understand the granulality of the interactions between DNA, RNA and proteins which is the base of all the drug discovery, precision medicine and targeted therapy research among many pother applications of the field."

Key Companies Operating in The Market

The key players in the global functional genomics market have been analyzed and profiled in the study, consisting of most product-based companies. Moreover, a detailed competitive benchmarking of the players operating in the global functional genomics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

The key players profiled in the report include Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Danaher. (Integrated DNA Technologies, Inc.), Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Illumina, Inc., Merck KGaA, MRM Proteomics, Pacific Biosciences of California, Inc., Perkin Elmer, Inc., Promega Corporation, QIAGEN, and Thermo Fisher Scientific Inc.

Key Questions Answered in the Report:

• How is the functional genomics market revolutionizing precision medicine therapeutics, influencing disease diagnosis and treatment, and other applications landscapes?
• What are the major market drivers, challenges, and opportunities in the global functional genomics market?
• What are the underlying structures resulting in the emerging trends within the global functional genomics market?
• How did the COVID-19 pandemic impact the global functional genomics market?
• What are the key development strategies that are being implemented by major players to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of functional genomics products?
• What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region in the market?
• What will be the growth rate of the global functional genomics market during the forecast period?
• How is each segment of the market expected to grow during the forecast period 2023-2033, and what revenue is anticipated to be generated by each of the segments?
• What are the growth opportunities for the functional genomics companies in the region of their operation?
• Who are the leading players with significant offerings in the global functional genomics market?
• Which companies are anticipated to be highly disruptive in the future, and why?

Global Functional Genomics Market Industry Overview

In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033. The growth in the global functional genomics market is expected to be driven by its increased applications especially in targeted therapy and precision medicine.

Market Lifecycle Stage

Functional genomics is the study of genes and their interactions in different biological processes. The field aims to narrow down the candidate genes or regions from the entire genome that can be analyzed in detail to understand the working of various biological processes. The workings of individual components of a biological system including various interactions at the DNA, RNA, and proteins level is analyzed at the genotypic as well as the phenotypic level. The field is focused on the dynamics of gene products which can be at a specific developmental stage during a disease. Functional genomics is used to link phenotypes to genotypes using the study findings.

According to BIS Research functional genomics products are used in DNA level (epigenomics), RNA level (transcriptomics), protein level (proteomics) or metabolite level (metabolomics). This includes all the products used in these fields' workflow before bioinformatics and data analysis. Together all these fields describe the transcripts, metabolites, and proteins of any biological system. The integration of all these pieces makes up the entire biological system that is being studied which makes up the field of functional genomics.

Impact

• For instance, in May 2022, Thermo Fisher Scientific, Inc. partnered with Qatar Foundation to develop a pan-Arab genotyping array. The intent behind this product launch was to be a cost-effective alternative to whole-genome sequencing and to provide greater diversity in genome-wide research studies under Qatar Genome Program.
• In September 2022, Illumina Inc. introduced the NovaSeqX Series (NovaSeq X and NovaSeq X Plus), which are next-generation sequencers designed for large-scale production. With the capability to sequence over 20,000 genomes per year, this new technology offers unparalleled accuracy and scalability.

Impact of COVID-19

In March 2019, the world was hit by a storm with the Sars-CoV-2 virus, which led to the entire world being shut down and everybody getting tested for the virus. As the amount of testing increased, it became important to increase the pace of testing as well. To do this, next-generation sequencers were set up at many clinical and diagnostic centers to sequence the genomes and transcriptomes of the virus as well as the infected patients to understand and procure treatments.

Recently, NGS technologies are increasingly being used for clinical diagnosis. The overall popularity of NGS sequencing for genome and transcriptome sequencing was increased during COVID-19 because of its use in the detection of coronavirus by the methods such as SARS-CoV-2 surveillance, detection, and the detection of new viruses.

In response to the COVID-19 pandemic and the impact on medical research at the National Institutes of Health (NIH) and the National Cancer Institute (NCI) both extended grant application deadlines, laid back reporting requirements, and offered flexibility on how the grant money is spent. The national government supported research work and offered medical researchers the flexibility to implement their skill set and knowledge in studying SARS-CoV-2. Due to this, the use of NGS during COVID-19 ended up increasing due to its use in COVID-19 testing.

In fact, even now, after the pandemic has subsided the effect lingers and the use of sequencing instruments is not expected to go down but to keep increasing over the next decade enhancing the fields for epigenomics, transcriptomics, proteomics and metabolomics as well.

Market Segmentation:

Segmentation 1: by Product

• Kits and Assays
• Instruments

As of 2022, the global functional genomics market (by product) was dominated by the kits and assays segment, holding a 58.12% market share.

Segmentation 2: by Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray
• Other

The global functional genomics market (by technology) is expected to be dominated by the next-generation sequencing (NGS) segment during the forecast period 2023-2033. This is because it is the most efficient and accurate technology currently available when it comes to gene analysis.

Segmentation 3: by Application

• Transcriptomics
• Epigenomics
• Proteomics
• Metabolomics

The global functional genomics market (by application) is expected to be dominated by the transcriptomics segment in the market during the forecast period 2023-2033. This is because this is one the oldest fields of functional genomics with much research and efficient tools already done, additionally it is easier to analyse RNAs as compared to proteins, thus the high revenue of this segment.

Segmentation 4: by End User

• Academic & Research Institutions
• Biotechnology and Biopharmaceutical Companies
• Other End Users

As of 2022, the global functional genomics market (by end user) was dominated by the academic and research institutions segment, holding a 60.32% market share.

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

North America is expected to dominate the global functional genomics market with a revenue of $4.21 billion in 2022. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 15.27% during the forecast period 2023-2033.

Recent Developments in Global Functional Genomics Market

• In September 2022, Thermo Fisher Scientific partnerered with the joint effort of Acdemia Sinica and multiple hospitals across the country, i.e., Taiwan Precision Medicine Initiative (TPMI) to advance the next phase of the large-scale predictive genomics study. The intent behind this partnership was to support its goal of genotyping 1 million people in Taiwan. TPMI reached the milestone of enrolling more than 500,000 participants in July, making it the largest study of its kind outside of the United States and Europe.

• In March 2022, Thermo Fisher Scientific collaborated with Symphogen and Servier to provide biopharmaceutical discovery and development laboratories with advanced tools and simplified processes for effective analysis of intricate therapeutic proteins, thereby supporting their research efforts.

• In July 2021, Pacific Biosciences of California, Inc. has sighned a agreement to acquire Omniome. This acquitision is likley to expand the portfolio in epigenetics segments

• In October 2022, Oxford Nanopore Technologies introduced the new PromethION 2 ("P2") Solo sequencer in the market. It is a high-yield sequencer that provides real-time whole genome sequencing, enabling more than just basic DNA analysis. With the capacity for comprehensive analysis of genetic variants, transcriptomic and epigenetic data on a single platform, this technology is aimed at driving scientific discovery to improve lives.

• In September 2022, Illumina Inc. introduced the NovaSeqX Series (NovaSeq X and NovaSeq X Plus), which are next-generation sequencers designed for large-scale production. With the capability to sequence over 20,000 genomes per year, this new technology offers unparalleled accuracy and scalability.

Demand - Drivers and Limitations

Following are the demand drivers for the global functional genomics market:

• Integration of Multi-omics Approaches for Patient Stratification
• Increasing Popularity of Epigenetics Leading to Vast Usage
• Increased Technological Advancements and Government Initiatives in the Functional Genomics Ecosystem

The market is expected to face some limitations too due to the following challenges:

• Limitation in Implementation of Data in Proteomics and Metabolomics
• Regulatory Compliance issues related to Functional Genomics Technology

How can this report add value to an organization?

• Product/Innovation Strategy: The report considers functional genomics kits and assays-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of more efficient instruments and tools of functional genomics is increasing researchers' trust in functional genomics.

• Growth/Marketing Strategy: The key components in functional genomics are the kits and assays along with the instruments for sample analysis. The advancements in the overall fucntioncal genomics ecosystem are influencing the growth of this market.

• Competitive Strategy: The key players in the global functional genomics market have been analyzed and profiled in the study, consisting of most product-based companies. Moreover, a detailed competitive benchmarking of the players operating in the global functional genomics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

Table of Contents

1 Markets

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
• 1.3 Market Scope
  • 1.3.1 Scope of the Study
  • 1.3.2 Key Questions Answered in the Report
• 1.4 Research Methodology
  • 1.4.1 Global Functional Genomics Market: Research Methodology
  • 1.4.2 Data Sources
  • 1.4.3 Market Estimation Model
  • 1.4.4 Criteria for Company Profiling

2 Market Overview

• 2.1 Functional Genomics Workflow Analysis
• 2.2 Future Potential
• 2.3 Impact of Functional Genomics
  • 2.3.1 Gene Therapy
  • 2.3.2 Drug Discovery and Development
  • 2.3.3 Gene Expression
  • 2.3.4 Single-Cell Analysis

3 Industry Insight

• 3.1 Legal and Regulatory Framework of Genetic Tests
  • 3.1.1 Diagnostic Test
• 3.2 Reimbursement Scenario

4 Market Dynamics

• 4.1 Overview
• 4.2 Market Drivers
  • 4.2.1 Integration of Multi-omics Approaches for Patient Stratification
  • 4.2.2 Increasing Popularity of Epigenetics Leading to Vast Usage
  • 4.2.3 Increased Technological Advancements and Government Initiatives in the Functional Genomics Ecosystem
• 4.3 Market Challenges
  • 4.3.1 Limitations in Implementation of Data in Proteomics and Metabolomics
  • 4.3.2 Regulatory Compliance Issues Related to Functional Genomics Technology
• 4.4 Market Opportunities
  • 4.4.1 Upsurge in Proteomic Approaches in Biomarker Discovery
  • 4.4.2 Rising Opportunities for Translational and Clinical Studies

5 Competitive Insight

• 5.1 Overview
• 5.2 Key Strategies and Developments
  • 5.2.1 Synergistic Activities
  • 5.2.2 Product Launches and Product Approvals
  • 5.2.3 Expansions
  • 5.2.4 Mergers and Acquisitions
  • 5.2.5 Investments and Other Activities
• 5.3 Market Share Analysis (2022)

6 Global Functional Genomics Market (By Product), 2022-2033

• 6.1 Overview
  • 6.1.1 Kits and Assays
  • 6.1.2 Instruments

7 Global Functional Genomics Market (By Technology), 2022-2033

• 7.1 Overview
  • 7.1.1 Next-Generation Sequencing (NGS)
  • 7.1.2 Polymerase Chain Reaction (PCR)
  • 7.1.3 Microarray
  • 7.1.4 Other Technologies

8 Global Functional Genomics Market (by Application), 2022-2033

• 8.1 Overview
• 8.2 Epigenomics
• 8.3 Transcriptomics
• 8.4 Proteomics
• 8.5 Metabolomics

9 Global Functional Genomics Market (by End User), 2022-2033

• 9.1 Overview
• 9.2 Academic and Research Institutions
• 9.3 Biotechnology and Biopharmaceutical Companies
• 9.4 Other End Users (Hospitals, Clinics, and Diagnostic Labs)

10 Global Functional Genomics Market (By Region), 2022-2033

• 10.1 Overview
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 U.K.
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest-of-Europe
• 10.4 Asia-Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Singapore
  • 10.4.6 Rest-of-Asia-Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest-of-Latin America
• 10.6 Rest-of-the-World

11 Company Profiles

• 11.1 Overview
• 11.2 Agilent Technologies, Inc.
  • 11.2.1 Company Overview
  • 11.2.2 Role of Agilent Technologies, Inc. in the Global Functional Genomics Market
  • 11.2.3 Financials
  • 11.2.4 Key Insights about the Financial Health of the Company
  • 11.2.5 Recent Developments
  • 11.2.6 Analyst Perspective
• 11.3 Becton, Dickinson and Company (BD)
  • 11.3.1 Company Overview
  • 11.3.2 Role of Becton, Dickinson and Company (BD) in the Global Functional Genomics Market
  • 11.3.3 Financials
  • 11.3.4 Key Insights about the Financial Health of the Company
  • 11.3.5 Analyst Perspective
• 11.4 Bio-Rad Laboratories, Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Functional Genomics Market
  • 11.4.3 Financials
  • 11.4.4 Key Insights about the Financial Health of the Company
  • 11.4.5 Recent Developments
  • 11.4.6 Analyst Perspective
• 11.5 Danaher. (Integrated DNA Technologies, Inc.)
  • 11.5.1 Company Overview
  • 11.5.2 Role of Danaher. (Integrated DNA Technologies, Inc.) in the Global Functional Genomics Market
  • 11.5.3 Financials
  • 11.5.4 Key Insights about the Financial Health of the Company
  • 11.5.5 Analyst Perspective
• 11.6 Exact Sciences Corporation
  • 11.6.1 Company Overview
  • 11.6.2 Role of Exact Sciences Corporation in the Global Functional Genomics Market
  • 11.6.3 Financials
  • 11.6.4 Key Insights about the Financial Health of the Company
  • 11.6.5 Recent Developments
  • 11.6.6 Analyst Perspective
• 11.7 F. Hoffmann-La Roche Ltd
  • 11.7.1 Company Overview
  • 11.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Functional Genomics Market
  • 11.7.3 Financials
  • 11.7.4 Key Insights about the Financial Health of the Company
  • 11.7.5 Recent Developments
  • 11.7.6 Analyst Perspective
• 11.8 Illumina, Inc.
  • 11.8.1 Company Overview
  • 11.8.2 Role of Illumina, Inc. in the Global Functional Genomics Market
  • 11.8.3 Financials
  • 11.8.4 Key Insights about the Financial Health of the Company
  • 11.8.5 Recent Developments
  • 11.8.6 Analyst Perspective
• 11.9 Merck KGaA
  • 11.9.1 Company Overview
  • 11.9.2 Role of Merck KGaA in the Global Functional Genomics Market
  • 11.9.3 Financials
  • 11.9.4 Key Insights about the Financial Health of the Company
  • 11.9.5 Analyst Perspective
• 11.1 MRM Proteomics
  • 11.10.1 Company Overview
  • 11.10.2 Role of MRM Proteomics in the Global Functional Genomics Market
  • 11.10.3 Analyst Perspective
• 11.11 Pacific Biosciences of California, Inc.
  • 11.11.1 Company Overview
  • 11.11.2 Role of Pacific Biosciences of California, Inc. in the Global Functional Genomics Market
  • 11.11.3 Financials
  • 11.11.4 Key Insights about the Financial Health of the Company
  • 11.11.5 Recent Developments
  • 11.11.6 Analyst Perspective
• 11.12 Perkin Elmer, Inc.
  • 11.12.1 Company Overview
  • 11.12.2 Role of PerkinElmer, Inc. in the Global Functional Genomics Market
  • 11.12.3 Financials
  • 11.12.4 Key Insights about the Financial Health of the Company
  • 11.12.5 Analyst Perspective
• 11.13 Promega Corporation
  • 11.13.1 Company Overview
  • 11.13.2 Role of Promega Corporation in the Global Functional Genomics Market
  • 11.13.3 Analyst Perspective
• 11.14 QIAGEN
  • 11.14.1 Company Overview
  • 11.14.2 Role of QIAGEN in the Global Functional Genomics Market
  • 11.14.3 Financials
  • 11.14.4 Key Insights about the Financial Health of the Company
  • 11.14.5 Recent Developments
  • 11.14.6 Analyst Perspective
• 11.15 Thermo Fisher Scientific Inc.
  • 11.15.1 Company Overview
  • 11.15.2 Role of Thermo Fisher Scientific Inc. in the Global Functional Genomics Market
  • 11.15.3 Financials
  • 11.15.4 Key Insights about the Financial Health of the Company
  • 11.15.5 Recent Developments
  • 11.15.6 Analyst Perspective